{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:26:57Z","timestamp":1787164017561,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFE0206500"],"award-info":[{"award-number":["2023YFE0206500"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273773"],"award-info":[{"award-number":["82273773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202408055"],"award-info":[{"award-number":["tsqn202408055"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117992","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:57:54Z","timestamp":1753113474000},"page":"117992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Further exploring the tolerant region II: Identification of 2,4,5-trisubstituted pyrimidines as HIV-1 reverse transcriptase allosteric inhibitors with desirable antiviral activities and reduced cytotoxicity"],"prefix":"10.1016","volume":"297","author":[{"given":"Zhenzhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhening","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-2214","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117992_bib1","unstructured":"https:\/\/www.who.int\/hiv\/data\/en\/, 2023 (The latest data on HIV released by WHO in 2023)."},{"key":"10.1016\/j.ejmech.2025.117992_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2020.09.004","article-title":"Timeline: HIV","volume":"183","author":"Agarwal-Jans","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117992_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/hiv.13557","article-title":"HIV cure: are we going to make history?","volume":"25","author":"Payra","year":"2024","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2025.117992_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.898449","article-title":"Benefits and risks of rapid initiation of antiretroviral therapy: a systematic review and meta-analysis","volume":"13","author":"Bai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117992_bib5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117992_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nsmb.2223","article-title":"HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism","volume":"19","author":"Das","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117992_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114217","article-title":"Natural products and synthetic analogues against HIV: a perspective to develop new potential anti-HIV drugs","volume":"233","author":"Popovi\u0107-Djordjevi\u0107","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib8","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/S2352-3018(22)00249-1","article-title":"Two-drug regimens for HIV treatment","volume":"9","author":"Gibas","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ejmech.2025.117992_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117992_bib10","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/hiv.13525","article-title":"Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: a cohort study from antiviral response cohort analysis (ARCA)","volume":"24","author":"Rancan","year":"2023","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2025.117992_bib12","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.ejmech.2025.117992_bib13","first-page":"330","article-title":"Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development","volume":"13","author":"Emamzadeh-Fard","year":"2013","journal-title":"Infect. Disord.: Drug Targets"},{"key":"10.1016\/j.ejmech.2025.117992_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116973","article-title":"Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors (2019-2023)","volume":"280","author":"Nie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib15","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis, and evaluation of Thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117992_bib16","article-title":"Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors","volume":"7","author":"Yang","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.117992_bib17","doi-asserted-by":"crossref","first-page":"15608","DOI":"10.1021\/acs.jmedchem.2c00576","article-title":"Lead optimization and avoidance of metabolic-perturbing motif developing novel diarylpyrimidines as potent HIV-1 NNRTIs","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116708","article-title":"Discovery of 2,4,6-trisubstituted pyrimidine derivatives as novel potent HIV-1 NNRTIs by exploiting the tolerant region II of the NNIBP","volume":"277","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112237","article-title":"In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP","volume":"193","author":"Kang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib20","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/jm1002233","article-title":"Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design","volume":"53","author":"Lansdon","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117992_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jmb.2003.12.055","article-title":"Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors","volume":"336","author":"Ren","year":"2004","journal-title":"J. Mol. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:50:41Z","timestamp":1776919841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"alternative-id":["S0223523425007573"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117992","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Further exploring the tolerant region II: Identification of 2,4,5-trisubstituted pyrimidines as HIV-1 reverse transcriptase allosteric inhibitors with desirable antiviral activities and reduced cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117992"}}